Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0876 • ACR Convergence 2025
Effect of QX002N on Clinical and Radiographic Outcomes in Ankylosing Spondylitis: Results from a Phase III Randomized, Double-blind, Placebo-Controlled Study
Xiaofeng Zeng¹, Shangzhu Zhang², SHENGYUN LIU³, Fengju Li⁴, xuebin wang⁵, LINGYUN SUN⁶, Hongwei Du⁷, Guixiu Shi⁸, yanling li⁹, hongwei zhang¹⁰, Liyun Zhang¹¹, Jian Wu¹², mingxuan zhou¹³, zhanqing gu¹⁴, yi zhao¹⁵, min fang¹⁶, Qingyi Song¹⁷ and ting wang¹⁷, ¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), ³The First Affiliated Hospital Of Zhengzhou University, zhengzhou, China (People's Republic), ⁴Puyang Olifield General Hospital, puyang, Henan, China (People's Republic), ⁵Binzhou Medical University Hospital, binzhou, Shandong, China (People's Republic), ⁶Nanjing Drum Tower Hospital, NANJING, China (People's Republic), ⁷Jinhua Municipal Central Hospital, Jinhua, China (People's Republic), ⁸The First Affiliated Hospital of Xiamen University, xiamen, Fujian, China (People's Republic), ⁹Hospital of Traditional Chinese Medicine of Zhongshan, 中山, Guangdong, China (People's Republic), ¹⁰The First People's Hospital of Foshan, foshan, Guangdong, China (People's Republic), ¹¹Shanxi Bethune Hosptial, Taiyuan, China (People's Republic), ¹²The First Affiliated Hospital of soochow University, Suzhou, China (People's Republic), ¹³The Second Affiliated Hospital of Fujian Medical University, quanzhou, Fujian, China (People's Republic), ¹⁴The First Hospital of Hebei Medical University, shijiazhuang, Hebei, China (People's Republic), ¹⁵Xuanwu Hospital, Capital Medical University, beijing, Beijing, China (People's Republic), ¹⁶Qyuns Therapeutics Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁷Qyuns Therapeutics CO., Ltd., Shanghai, China (People's Republic)
Background/Purpose: QX002N is a novel high-affinity monoclonal antibody (mAb) that selectively targets IL-17A.In the phase II clinical study, QX002N was well tolerated and rapidly reduced…
Abstract Number: 2334 • ACR Convergence 2025
Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index
Dafne capelusnik¹, Philip Gardiner², Elena Nikiphorou³, Désirée Van Der Heijde⁴, Robert Landewé⁵, Astrid Van Tubergen⁶, Annelies Boonen⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Altnagelvin Hospital, Londonderry, United Kingdom, ³King’s College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁶Maastricht university, Maastricht, Netherlands, ⁷Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The MOBILITY study, a study on spinal mobility measures in healthy individuals, showed that the Bath Ankylosing Spondylitis Metrology Index (BASMI) often overestimates spinal…
Abstract Number: 1466 • ACR Convergence 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Walter P. Maksymowych¹, Robert G. W. Lambert², Victoria Navarro-Compan³, Xenofon Baraliakos⁴, Jason Coarse⁵, Natasha de Peyrecave⁶ and Mikkel Ostergaard⁷, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB, Morrisville, NC, ⁶UCB, Brussels, Belgium, ⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Spinal inflammation and structural progression are key features of radiographic axial spondyloarthritis (r-axSpA).1 Canada-Denmark (CANDEN) scoring enables anatomical-based assessments of MRI inflammatory and structural…
Abstract Number: 1420 • ACR Convergence 2025
A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Isadora Small¹, Anuya Natu² and Augustine Manadan³, ¹The Latin School of Chicago, Chicago, IL, ²John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with systemic complications that may contribute to increased mortality risk. This study examines the characteristics and…
Abstract Number: 0854 • ACR Convergence 2025
The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study
Walter P. Maksymowych¹, Désirée van der Heijde², Liron Caplan³, Robert Landewé⁴, Lianne S. Gensler⁵, Pedro Machado⁶, Alexandre Sepriano⁷, Floris A. van Gaalen², Miranda van Lunteren², Ben Vandermeer⁸, Servet Akar⁹, Sibel Aydin¹⁰, Xenofon Barliakos¹¹, Wilson bautista molano¹², Stephanie Bernard¹³, RUBEN BURGOS-VARGAS¹⁴, John Carrino¹⁵, Alberto Cauli¹⁶, Jonathan Chan¹⁷, Abhijeet Danve¹⁸, Torsten Diekhoff¹⁹, Maxime Dougados²⁰, iris Eshed²¹, Warren Fong²², Rodrigo García Salinas²³, Hildrun Haibel²⁴, Nigil Haroon²⁵, Kay-Geert Hermann²⁶, Lennart Jans²⁷, Anne Jurik²⁸, Uta Kiltz²⁹, Tae-Jong Kim³⁰, Robert G. W. Lambert³¹, Clementina López Medina³², Ennio Lubrano³³, Marina Magrey³⁴, Vikas Majithia³⁵, Helena Marzo-Ortega³⁶, Philip J. Mease³⁷, Victoria Navarro-Compan³⁸, John O'Neill³⁹, Mikkel Ostergaard⁴⁰, Salih Ozgocmen⁴¹, Susanne Pedersen⁴², Fernando Pimentel-Santos⁴³, Denis Poddubnyy⁴⁴, Fabian Proft⁴⁵, Sofia Ramiro⁴⁶, Monique Reijnierse⁴⁷, John Reveille⁴⁸, Ruxandra Elena Schiotis⁴⁹, Hasan Tahir⁵⁰, Michael Tuite⁵¹, Filip Van den Bosch⁵², Runshen Wang⁵³, Ulrich Weber⁵⁴, James Cheng-Chung⁵⁵, Joachim Sieper⁵⁶, Atul Deodhar⁵⁷, and Martin Rudwaleit⁵⁸, ¹Department of Medicine, University of Alberta, 568 Heritage Building, Edmonton, AB, Canada, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medicine Service, Rocky Mountain Regional VAMC, Aurora, CO, ⁴Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁷Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey, ¹⁰Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹¹Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ¹²University Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, ¹³Department of Radiology, Brooke Army Medical Center, Fort Sam Houston, TX, ¹⁴Department of Rheumatology, Hospital General de Mexico, Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Ciudad de México, Mexico, ¹⁵Department of Radiology and Imaging, Hospital for Special Surgery, New York, NY, ¹⁶Rheumatology Unit, Department of Medicine and Public Health, AOU and University of Cagliari, Cagliari, Italy, ¹⁷Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁸Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ¹⁹Department of Radiology, Immanuel Clinic Ruedersdorf, Brandenburg Medical School, Ruedersdorf, Germany, ²⁰Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ²¹Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer affiliated with School of Medicine, Tel Aviv University, Tel Aviv, Israel, ²²Department of Medicine, Singapore General Hospital, Singapore, Singapore, ²³Hospital Italiano La Plata, La Plata, Argentina, ²⁴Charite- University Medicine Berlin Campus Benjamin Franklin, Berlin, Germany, ²⁵Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ²⁶Department of Radiology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²⁷Department of Radiology, Ghent University Hospital, Ghent, Belgium, ²⁸Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ²⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³⁰Department of Medicine, Chonnam National University Hospital, Seoul, Republic of Korea, ³¹University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ³²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³³Department of Medicine, Università deglia Studi del Molise, Campobasso, Italy, ³⁴Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ³⁵Mayo Clinic Hospital, Jacksonville, FL, ³⁶NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ³⁷Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³⁸Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³⁹Department of Radiology, McMaster University, Hamilton, ON, Canada, ⁴⁰Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ⁴¹Department of Rheumatology, Istinye University/Faculty of Medicine, Istanbul, Turkey, ⁴²Department of Medicine, Rigshopital, University of Copenhagen, Copenhagen, Denmark, ⁴³NOVA Medical School, Universidade NOVA e Lisboa, Lisboa, Portugal, ⁴⁴Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁴⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴⁶Leiden University Medical Center, Zuyderland Medical Center, Netherlands, ⁴⁷Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁴⁸Department of Medicine, University of Texas Medical Center, Houston, TX, ⁴⁹Clinical Hospital of Infectious Diseases, Rheumatology Department, Cluj-Napoca, Romania, ⁵⁰Department of Medicine, Royal Free NHS Foundation Trust, London, United Kingdom, ⁵¹Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI ⁵²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵³Division of Rheumatology, Columbia University Irving Medical Center and Garden State Rheumatology Consultants, Union, NJ, ⁵⁴Medical Centre of Zenit, Department of Rheumatology, Schaffhausen, Switzerland, ⁵⁵Department of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ⁵⁶Department of Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany ⁵⁷Division of Arthritis and Rheumatic Diseases, Oregon Health & Sciences University, Portland, OR, ⁵⁸Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany

Background/Purpose: The 2009 ASAS classification criteria had sensitivity (Sn) of 83% and specificity (Sp) of 84% for a rheumatologist diagnosis of axial spondyloarthritis (axSpA). Given…
Abstract Number: 2333 • ACR Convergence 2025
Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
Dafne capelusnik¹, Philip Gardiner², Annelies Boonen³, Elena Nikiphorou⁴ and Sofia Ramiro⁵, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Altnagelvin Hospital, Londonderry, United Kingdom, ³Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ⁴King’s College London, London, United Kingdom, ⁵Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The MOBILITY study showed that BASMI often misclassifies spinal mobility, especially in older and taller individuals. To address this, the Corrected AxSpA Metrology Index…
Abstract Number: 1465 • ACR Convergence 2025
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compan¹, Philip J. Mease², Lianne S. Gensler³, Martin Rudwaleit⁴, Yael Klionsky⁵, Jayne Stigler⁶, Erin Mancl⁷, Shirley Chen⁸, Jamie Urbanik⁹ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁵Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁶AbbVie, Round Lake, IL, ⁷AbbVie, Chicago, IL, ⁸AbbVie, Somerset, NJ, ⁹AbbVie, Grayslake, IL, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Treatment with the oral JAK inhibitor upadacitinib (UPA) has shown efficacy and safety in patients with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA,…
Abstract Number: 1418 • ACR Convergence 2025
Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased cardiovascular risk, potentially exacerbated by NSAID therapy. However, the additional impact of Type 2 diabetes mellitus (T2DM)…
Abstract Number: 0817 • ACR Convergence 2025
More than 40% of Older Adults with Rheumatic Diseases Are Prescribed Opioid Medications
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Patients with rheumatic diseases commonly experience acute or chronic pain that may lead to both short- and long-term opioid use. Many patients do not…
Abstract Number: 2638 • ACR Convergence 2025
ASembleNet: A Hybrid AI Model for MRI-Based Classification of Ankylosing Spondylitis
Miral Gharib¹, Amith Khandakar², Mohamed Arselene Ayari³ and Samar Al emadi⁴, ¹hamad medical corporation, Doha, Qatar, ²Department of Electrical Engineering, College of Engineering, Qatar University, Doha, Qatar, Doha, Qatar, ³Department of Civil and Environmental Engineering, College of Engineering, Qatar University, Doha, Qatar, ⁴Hamad medical corporation, Doha, Qatar
Background/Purpose: Ankylosing spondylitis (AS) is a progressive inflammatory disease with delayed diagnosis due to subtle early imaging findings. We present ASembleNet, a deep learning model…
Abstract Number: 2331 • ACR Convergence 2025
Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Marc van Essen¹, Dafne capelusnik², Désirée Van Der Heijde³, Robert Landewé⁴, Wim van Lankveld⁵, Astrid Van Tubergen⁶, Sofia Ramiro⁷ and Annelies Boonen⁸, ¹Maastricht University, Zeist, Netherlands, ²Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁵HAN University of Applied Sciences, Arnhem, Netherlands, ⁶Maastricht university, Maastricht, Netherlands, ⁷Leiden University Medical Center, Bunde, Netherlands, ⁸Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands
Background/Purpose: To identify patient characteristics and disease phenotypes associated with coping strategies in axial spondyloarthritis (axSpA), and assess whether coping strategies change over time.Methods: Data…
Abstract Number: 1454 • ACR Convergence 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Philip J. Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Myriam Manente⁴, Luke Peterson⁵, Katy White⁶, Peter Nash⁷ and Lianne S. Gensler⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³UCB, Slough, England, United Kingdom, ⁴UCB, Braine-L'Alleud, Belgium, ⁵UCB, Morrisville, NC, ⁶UCB, Slough, United Kingdom, ⁷School of Medicine, Griffith University, Brisbane, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…
Abstract Number: 1410 • ACR Convergence 2025
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Connor Vershel¹, Mark Hwang², John Reveille³, Seokhun Kim⁴, Matthew A. Brown⁵, Michael Weisman⁶, Mariko Ishimori⁶ and Michael Ward⁷, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, ²UTHealth Houston, Houston, TX, ³Department of Medicine, University of Texas Medical Center, Houston, TX, ⁴UTHealth Houston, Houston, ⁵Genomics England, London, United Kingdom, ⁶Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…
Abstract Number: 0547 • ACR Convergence 2025
Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
Patricia Remalante-Rayco¹, Laura Passalent², Manal Alnasser³, Tina Chim¹, Robert Inman¹, Nigil Haroon⁴ and Denis Poddubnyy⁵, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³King Abdulaziz Medical City, Riyadh, Saudi Arabia, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) group has recently introduced a consensus-based definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA) to identify patients with…
Abstract Number: 2636 • ACR Convergence 2025
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Raj Sengupta¹, Anthony Marotta², Walter P. Maksymowych³, Charlotte Cavill⁴, Stephen Bleakley² and Norma Biln⁵, ¹Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, ²Augurex Life Sciences Corp, Vancouver, BC, Canada, ³Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁴Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, ⁵Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: People with axial spondyloarthritis (axSpA), typically present with persistent back pain and experience up to a 10-year diagnostic delay that may lead to irreversible…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].